An open-label extension study of long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

An open-label extension study of long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Acronyms INPULSIS-ON
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 28 Nov 2017 Planned End Date changed from 1 Dec 2018 to 30 Dec 2018.
    • 23 Oct 2017 Results of long-term efficacy analysis presented at the 2017 CHEST Annual Meeting, according to a Boehringer Ingelheim Pharmaceuticals media release.
    • 23 Oct 2017 Results of long-term efficacy analysis presented in a Boehringer Ingelheim Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top